Predict your next investment

Antios Therapeutics company logo
HEALTHCARE | Drug Development
antiostherapeutics.com

See what CB Insights has to offer

Executives

2

Board of Directors

2

Antios Therapeutics Board of Directors

2 Board of directors

Antios Therapeutics has 2 board of directors, including Gerry Brunk.

Name

Firm

Work History

Other Seats

Gerry Brunk

With over 28 years of investment, consulting and entrepreneurial experience in the health care industry, Gerry has helped build life sciences companies at all stages of development. He focuses on investments in a range of therapeutic areas in the biotechnology and medical device sectors, including infectious diseases, neurology, cardiovascular disease, gene therapy and medical robotics. Gerry manages Lumira Ventures’ Boston office, which he established when he joined the firm in 2002. Prior to joining Lumira Ventures, Gerry was an entrepreneur in the life sciences sector, founding and serving in a variety of management and board capacities at several venture capital-funded companies. Earlier in his career he was an engagement manager in the health care practice of The Boston Consulting Group, where he advised pharmaceutical and biotechnology firms on strategic issues including portfolio management, corporate partnering, R&D productivity, new product launches, disease management initiatives, acquisitions and post-merger integration. Gerry began his career as a member of the investment banking group of Credit Suisse First Boston in New York where his clients included public and private health care companies.

Bardy Diagnostics, BAROnova, Cardiac Dimensions, Corvia Medical, Cyrano Therapeutics, Endotronix, enGene, and HistoSonics

Nicole Vitullo

Nicole joined Domain in 1999 and became a partner in 2004. With extensive experience in both public and private investing, Nicole’s current board memberships include Achillion Pharmaceuticals (Chair), Antios Therapeutics, Celtaxsys, Esperion Therapeutics and Marinus Pharmaceuticals. Additionally, she was a former board observer at Iterum Therapeutics. Past board memberships include Calixa Therapeutics (sold to Cubist Pharmaceuticals), Celator Pharmaceuticals (sold to Jazz Pharmaceuticals), Cerexa (sold to Forest Laboratories), Durata Therapeutics (sold to Actavis), Onyx Pharmaceuticals and VentiRx Pharmaceuticals (sold to Celgene). In addition to investment responsibilities, Nicole is involved with the liquidation and distribution strategies for the public companies in Domain’s venture capital portfolios. For more than a decade, Nicole was responsible for Domain Public Equity Partners L.P., a fund focused on private investments in public companies. Previous to Domain, Nicole was senior vice president at Rothschild Asset Management, Inc. where she had responsibility for the U.S. public market investments of International Biotechnology Trust plc and Biotechnology Investments Limited. Previous to Rothschild, Nicole served as the director of corporate communications and investor relations at Cephalon, a publicly traded biotechnology company. Prior to Cephalon, Nicole spent 12 years at Eastman Kodak, where she held a number of positions including corporate development, where she was involved in the development and management of Kodak’s venture capital activities. She received her B.A. in mathematics and her MBA in finance from University of Rochester.

Abrexa Pharmaceuticals, Achillion Pharmaceuticals, Achillion Pharmaceuticals, Celator Pharmaceuticals, Celtaxsys, Esperion Therapeutics, Marinus Pharmaceuticals, Netgenics, Psyadon Pharmaceuticals, VentiRx Pharmaceuticals, and Vicuron Pharmaceuticals

Name

Gerry Brunk

Nicole Vitullo

Firm

Work History

With over 28 years of investment, consulting and entrepreneurial experience in the health care industry, Gerry has helped build life sciences companies at all stages of development. He focuses on investments in a range of therapeutic areas in the biotechnology and medical device sectors, including infectious diseases, neurology, cardiovascular disease, gene therapy and medical robotics. Gerry manages Lumira Ventures’ Boston office, which he established when he joined the firm in 2002. Prior to joining Lumira Ventures, Gerry was an entrepreneur in the life sciences sector, founding and serving in a variety of management and board capacities at several venture capital-funded companies. Earlier in his career he was an engagement manager in the health care practice of The Boston Consulting Group, where he advised pharmaceutical and biotechnology firms on strategic issues including portfolio management, corporate partnering, R&D productivity, new product launches, disease management initiatives, acquisitions and post-merger integration. Gerry began his career as a member of the investment banking group of Credit Suisse First Boston in New York where his clients included public and private health care companies.

Nicole joined Domain in 1999 and became a partner in 2004. With extensive experience in both public and private investing, Nicole’s current board memberships include Achillion Pharmaceuticals (Chair), Antios Therapeutics, Celtaxsys, Esperion Therapeutics and Marinus Pharmaceuticals. Additionally, she was a former board observer at Iterum Therapeutics. Past board memberships include Calixa Therapeutics (sold to Cubist Pharmaceuticals), Celator Pharmaceuticals (sold to Jazz Pharmaceuticals), Cerexa (sold to Forest Laboratories), Durata Therapeutics (sold to Actavis), Onyx Pharmaceuticals and VentiRx Pharmaceuticals (sold to Celgene). In addition to investment responsibilities, Nicole is involved with the liquidation and distribution strategies for the public companies in Domain’s venture capital portfolios. For more than a decade, Nicole was responsible for Domain Public Equity Partners L.P., a fund focused on private investments in public companies. Previous to Domain, Nicole was senior vice president at Rothschild Asset Management, Inc. where she had responsibility for the U.S. public market investments of International Biotechnology Trust plc and Biotechnology Investments Limited. Previous to Rothschild, Nicole served as the director of corporate communications and investor relations at Cephalon, a publicly traded biotechnology company. Prior to Cephalon, Nicole spent 12 years at Eastman Kodak, where she held a number of positions including corporate development, where she was involved in the development and management of Kodak’s venture capital activities. She received her B.A. in mathematics and her MBA in finance from University of Rochester.

Other Seats

Bardy Diagnostics, BAROnova, Cardiac Dimensions, Corvia Medical, Cyrano Therapeutics, Endotronix, enGene, and HistoSonics

Abrexa Pharmaceuticals, Achillion Pharmaceuticals, Achillion Pharmaceuticals, Celator Pharmaceuticals, Celtaxsys, Esperion Therapeutics, Marinus Pharmaceuticals, Netgenics, Psyadon Pharmaceuticals, VentiRx Pharmaceuticals, and Vicuron Pharmaceuticals

Antios Therapeutics Management Team

2 Team Members

Antios Therapeutics has 2 executives. Antios Therapeutics's current Chief Executive Officer, President is Gregory Mayes.

Name

Work History

Title

Status

Gregory Mayes

Chief Executive Officer, President

Current

Douglas Mayers

Cocrystal Pharma, Idenix Pharmaceuticals, Boehringer Ingelheim, and U.S. Navy

Chief Medical Officer

Current

Name

Gregory Mayes

Douglas Mayers

Work History

Cocrystal Pharma, Idenix Pharmaceuticals, Boehringer Ingelheim, and U.S. Navy

Title

Chief Executive Officer, President

Chief Medical Officer

Status

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.